Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Economic information and modeling report

Modeling overview

30 evidence topics · 19 sources

Summary

  • Model structure (NICE TA1199, nirogacestat): a semi-Markov model comparing nirogacestat with best supportive care, to which the EAG added chemotherapy; 28-day cycles with a half-cycle correction to drug costs over a lifetime horizon; 5 health states (stable disease, complete response, partial response, progressed disease, death). Comparators were combined as a basket weighted by confidential SpringWorks 2024 market research, and the committee assumed that chemotherapy was equivalent to nirogacestat for PFS.
  • Utilities: De-Fi did not collect EQ-5D data. The company base case used soft-tissue sarcoma values from Shingler et al. 2013 (0.263 for progressed disease); the committee preferred EQ-5D values from Reichardt et al. 2012 (0.560 for progressed disease). The De-Fi QLQ-C30 data mapped to EQ-5D are confidential.
  • Treatment duration: the committee assumed that 5% of people continue treatment into year 3 and that 10% of those in complete response, partial response, or stable disease are retreated at year 3 for up to 1 year. The NICE resource impact template assumes 1 year of treatment, the G-BA assumes one year (365 days), and Immunome states that patients may receive “~1.5–2 years of treatment”.
  • Prices: nirogacestat U.S. WAC of $7,746.58 per package (01/05/2026), England list price of £15,189.04 per 56 pack of 150 mg tablets with a confidential discount, and German annual treatment cost of €260,760.82 per patient; sorafenib at $309/day at Medicare Part D rates (Johns et al. 2023).
  • Patient numbers: SpringWorks estimates of 5,500 to 7,000 U.S. patients actively managed per year (market research) and approximately 11,000 receiving physician care (ICD-10 claims); Immunome's “10-11k Actively Managed Patients (US)”; 223 people eligible in England, derived from a soft-tissue sarcoma prevalence of 5.55 per 10,000 adults, 3% of which are desmoid tumors, an incidence of 4 per 1,000,000 adults, and 40% progressing; and approximately 350 to 630 patients in Germany.
  • Other analyses: a SpringWorks-supported analysis of nirogacestat in DeFi (Malaviya et al. 2025) weighted health states with fixed utilities of 1.0, 0.5, and 0.5 over 20.6 months and reported a gain of 71.60 days versus placebo; it included no patient-reported utility data.
  • No budget impact model of varegacestat was found: every heading of the budget impact model section of this report reads No evidence found.

NICE TA1199 economic model structure: semi-Markov model with 28-day cycles, a lifetime horizon, and 5 health states

“The company submitted a semi-Markov model comparing nirogacestat with 'best supportive care' for treating progressing desmoid tumours that needed systemic treatment.” (opens the source at this quote in a new tab)

“The EAG updated the model to also include chemotherapy as a comparator for its base case, using evidence from the NMA (see section 3.5).” (opens the source at this quote in a new tab)

“The model applied 28‑day cycles, with a half-cycle correction to drug costs, over a lifetime horizon.” (opens the source at this quote in a new tab)

“The model contained 5 health states:” (opens the source at this quote in a new tab)

“stable disease” (opens the source at this quote in a new tab)

“complete response” (opens the source at this quote in a new tab)

“partial response” (opens the source at this quote in a new tab)

“progressed disease” (opens the source at this quote in a new tab)

“death.” (opens the source at this quote in a new tab)

“The health states were used in 2 different phases – during and after treatment, between which the structure and health-state interactions differed.” (opens the source at this quote in a new tab)

“The committee concluded that the overall structure of the model was suitable for decision making. The committee preferred to apply higher resource-use values from the EAG base case, because this better reflected clinical practice.” (opens the source at this quote in a new tab)

NICE TA1199 comparators: best supportive care and chemotherapy, combined as a basket comparator

“They thought that off-label chemotherapy would be used in about 30% to 50% of cases, particularly for sporadic tumours (see section 3.2).” (opens the source at this quote in a new tab)

“So, the committee concluded that 'best supportive care' (symptom management) and chemotherapy were the 2 relevant comparators in this evaluation.” (opens the source at this quote in a new tab)

“The basket comparator reflected the estimated mix of treatments that nirogacestat is expected to displace in NHS clinical practice, with the proportions of people having chemotherapy and best supportive care adding up to 100%.” (opens the source at this quote in a new tab)

“Incremental costs and quality-adjusted life years (QALYs) for chemotherapy and best supportive care were weighted according to their estimated use in clinical practice and combined to generate a blended ICER. This was based on UK usage data from a market research study done by SpringWorks Therapeutics in 2024.” (opens the source at this quote in a new tab)

“The company considered both the SpringWorks Therapeutics 2024 market research study and the ongoing ATU study to be confidential, so the estimates of treatment use cannot be reported here.” (opens the source at this quote in a new tab)

“Despite the uncertainty associated with estimating treatment proportions, it concluded that the proportions of best supportive care and chemotherapy proposed by the company were appropriate for decision making.” (opens the source at this quote in a new tab)

NICE TA1199 utility values: soft-tissue sarcoma proxies in the absence of EQ-5D data from De-Fi

“Although the De‑Fi trial did not collect EQ-5D data, it did collect quality-of-life data using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30.” (opens the source at this quote in a new tab)

“The utility values in the company base case were instead informed by published utility values from people with soft-tissue sarcoma (Shingler et al. 2013).” (opens the source at this quote in a new tab)

“The EAG stated that the utility value for progressed disease in the company base case was implausibly low for people with desmoid tumours (0.263). It explained that Shingler et al. was a time-trade-off study, which does not align with the NICE reference case.” (opens the source at this quote in a new tab)

“But, because this data was not provided, the EAG preferred to use utility values based on EQ-5D data from a clinical trial of people with soft-tissue sarcoma (Reichardt et al. 2012). This resulted in a utility value of 0.560 for progressed disease.” (opens the source at this quote in a new tab)

“At the second committee meeting, the company presented the EORTC QLQ-C30 quality-of-life data from De‑Fi, mapped to EQ-5D using the method from Young et al. (2015). These utilities are considered confidential by the company and so cannot be reported here.” (opens the source at this quote in a new tab)

“The committee noted that although there was uncertainty with using soft-tissue sarcoma as a proxy, it was reasonable in this instance because no other reliable utility evidence for desmoid tumours was available.” (opens the source at this quote in a new tab)

“So, it concluded that the utilities from the Reichardt et al. study were the most appropriate proxy utilities available.” (opens the source at this quote in a new tab)

“The committee concluded that pain would be reflected in the proxy soft-tissue sarcoma utility values but acknowledged that using a proxy carries a level of uncertainty.” (opens the source at this quote in a new tab)

NICE TA1199 treatment duration, discontinuation, and retreatment assumptions

NICE TA1199 resource impact: eligible population and uptake of nirogacestat in England

Eligible population and uptakeNumber of people eligibleUptake for nirogacestat (%)Number of people starting treatment with nirogacestat each year
“Current practice”“223”“0”“0”
“Year 1”“223”“50”“112”
“Year 2”“195”“60”“117”
“Year 3”“166”“75”“125”

G-BA basis for treatment costs and patient numbers: pack price, consumption, and uncertainty

“The G-BA takes into account the patient numbers stated in the pharmaceutical company's dossier, which are, however, subject to uncertainty overall. There were methodological limitations and uncertainty regarding the percentages of desmoid tumours, which also relate exclusively to inpatients, under ICD-10 code D48.1. Furthermore, patients who had been ill for more than 5 years were not considered.” (opens the source at this quote in a new tab)

“If no maximum treatment duration is specified in the product information, the treatment duration is assumed to be one year (365 days), even if the actual treatment duration is different from patient to patient and/or is shorter on average.” (opens the source at this quote in a new tab)

“The annual treatment costs shown refer to the first year of treatment.” (opens the source at this quote in a new tab)

“730 x 300 mg” (opens the source at this quote in a new tab)

“Nirogacestat 150 mg” (opens the source at this quote in a new tab)

“56 FCT” (opens the source at this quote in a new tab)

“€ 21,213.56” (opens the source at this quote in a new tab)

“€ 20,003.57” (opens the source at this quote in a new tab)

“In addition, the active ingredient sorafenib can be prescribed for off-label use since August 2024 for the treatment of adults with progressing desmoid tumours who have demonstrated disease progression and require treatment (see Annex VI to the Pharmaceuticals Directive).” (opens the source at this quote in a new tab)

U.S. incidence and actively managed population estimated by SpringWorks Therapeutics

Quality-adjusted time without symptoms or toxicity analysis of nirogacestat in DeFi, ISPOR Europe 2025

“Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe; November 9–12, 2025; Glasgow, Scotland” (opens the source at this quote in a new tab)

“This presentation was supported by SpringWorks Therapeutics, Inc.” (opens the source at this quote in a new tab)

“TB is an employee of SpringWorks Therapeutics, Inc.” (opens the source at this quote in a new tab)

“Each health state was weighted with fixed utility values (UTWiST=1.0, UTOX=0.5, UREL=0.5), consistent with prior Q-TWiST literature, to evaluate trade-off between treatment-related toxicity and survival outcomes” (opens the source at this quote in a new tab)

“The analysis utilized the double-blind phase of the DeFi trial to maintain randomization and minimize confounding” (opens the source at this quote in a new tab)

“Outcomes were assessed over 20.6 months, which corresponds to the median treatment duration for nirogacestat” (opens the source at this quote in a new tab)

“The model provided the option to include background mortality that was adjusted for the disease using a standardized mortality ratio of 3.70.” (opens the source at this quote in a new tab)

“The estimated 5-year overall survival (OS) for patients is 96%” (opens the source at this quote in a new tab)

“Patients treated with nirogacestat had statistically significant and superior Q-TWiST gain of 71.60 days (P<.001) and a clinically important relative gain of 11.52% versus placebo” (opens the source at this quote in a new tab)

“This analysis did not include patient-reported utility data, preventing insight into real-world quality of life” (opens the source at this quote in a new tab)